Help reinstate immediate R&D expensing


Since 2022, businesses have been prevented from immediately deducting their domestic R&D expenses. Negotiators are actively working to reverse this policy and include a solution in a legislative package that Congress will consider early this year. This is a critical issue for the bioeconomy in CA.

Join CLS and BIO in encouraging Congress to ensure that the tax code supports innovation. ACT NOW.